Kazunari K (kazushige) Yokoyama | Molecular Biology | Best Researcher Award

Best Researcher Award

Kazunari K (kazushige) Yokoyama
Affiliation Kaohsiung Medical University
Country Taiwan
Scopus ID 7401877315
Documents 241
Citations 8,317
h-index 52
Subject Area Molecular Biology, Genetics, Cancer Biology, Stem Cell Research
Event World Science Awards
ORCID 0000-0001-8508-7587

Kazunari K (kazushige) Yokoyama
Kaohsiung Medical University, Taiwan

Kazunari K. Yokoyama, officially known as Kazushige Yokoyama, is a distinguished molecular biologist, geneticist, and biomedical researcher whose scientific contributions have significantly influenced the fields of transcription factor biology, chromatin remodeling, stem cell research, cancer biology, oxidative stress, and gene regulation. His academic career spans more than four decades across leading institutions in Japan, the United States, France, China, and Taiwan. Through pioneering studies on AP-1 transcription factors, JDP2 signaling, antisense nucleic acid technologies, and stem-cell-associated molecular mechanisms, he has established an internationally recognized scientific legacy.[1]

Abstract

Kazunari K. Yokoyama has built an internationally respected research career centered on molecular genetics, cancer biology, stem cell science, transcriptional regulation, and chromatin dynamics. His scientific contributions encompass foundational discoveries in AP-1 transcription factor signaling, JDP2-mediated transcriptional repression, oxidative stress responses, and gene regulatory networks. With more than 300 scholarly publications, over 11,760 citations, and an h-index exceeding 62, his work has generated substantial influence within molecular biology and biomedical research communities worldwide.[1]

Keywords

Molecular Biology, Genetics, Cancer Research, Stem Cell Biology, AP-1 Signaling, JDP2, Chromatin Remodeling, Gene Regulation, Oxidative Stress, Transcription Factors, Redox Biology, Biomedical Research, Antisense Technology, Cell Therapy, Environmental Medicine.

Introduction

Professor Yokoyama’s scientific journey began with formal training in agricultural chemistry and biochemical sciences before progressing into advanced molecular biology research. Following doctoral studies at the University of Tokyo, he expanded his expertise through research appointments at the Albert Einstein College of Medicine and the City of Hope National Medical Center in the United States. His subsequent leadership positions at RIKEN and Kaohsiung Medical University enabled him to establish major research programs focused on gene regulation, cancer stem cells, developmental biology, and biomedical innovation.[2]

Research Profile

The research portfolio of Professor Yokoyama reflects sustained excellence across multiple domains of molecular and cellular biology. His work has integrated fundamental biological mechanisms with translational biomedical applications. Throughout his career, he has led major scientific initiatives involving DNA banking, gene engineering, stem cell biology, and cancer therapeutics while fostering extensive international collaborations among institutions in Asia, Europe, and North America.[2]

  • Molecular Genetics and Gene Regulation
  • Cancer Stem Cell Biology
  • Transcription Factor Networks
  • Chromatin Remodeling Mechanisms
  • Oxidative Stress and Redox Signaling
  • Environmental Medicine
  • Antisense RNA and DNA Therapeutics

Research Contributions

Professor Yokoyama’s most influential scientific achievements involve the discovery and characterization of transcriptional regulatory mechanisms associated with AP-1 complexes and JDP2 signaling pathways. His studies clarified how transcription factors interact with chromatin structures to regulate cellular differentiation, proliferation, and oncogenic transformation.[3]

  • Pioneering studies on AP-1 transcription factor biology.
  • Discovery and functional characterization of JDP2-mediated transcriptional repression.
  • Advances in chromatin remodeling and epigenetic regulation.
  • Contributions to stem cell differentiation and developmental biology.
  • Development of antisense nucleic acid therapeutic strategies.
  • Research linking oxidative stress pathways to cancer progression.
  • Investigations into cancer stem-cell-targeted therapeutic approaches.

Publications

The publication record of Professor Yokoyama exceeds 300 peer-reviewed articles, reviews, and scientific reports. His work has appeared in leading journals covering molecular biology, genetics, oncology, stem cell science, and biomedical research. Several publications have become highly cited references within their respective disciplines.[1]

  • AP-1 transcription factor signaling and cellular regulation.
  • JDP2-mediated transcriptional control mechanisms.
  • Stem cell differentiation and pluripotency studies.
  • Chromatin modification and epigenetic regulation.
  • Cancer stem cell biology and therapeutic innovation.

Research Impact

The impact of Professor Yokoyama’s scholarship is reflected by more than 11,760 citations, an h-index exceeding 62, and recognition among highly influential scientists worldwide. His inclusion in internationally recognized researcher rankings and participation in global collaborative projects demonstrate sustained influence on both fundamental biological sciences and translational medicine.[1]

  • 300+ peer-reviewed publications.
  • 11,760+ scholarly citations.
  • h-index above 62.
  • International collaborations across Asia, Europe, and North America.
  • Leadership roles in DNA banking and gene engineering initiatives.

Award Suitability

Professor Kazunari K. Yokoyama demonstrates exceptional qualifications for international recognition in molecular biology and biomedical sciences. His sustained record of scientific innovation, extensive publication output, international academic leadership, and measurable scholarly impact align strongly with the evaluation criteria commonly employed by prestigious global research awards. His contributions have advanced understanding of transcriptional regulation, stem cell biology, and cancer therapeutics while providing important foundations for future biomedical discoveries.[2]

Conclusion

Kazunari K. Yokoyama’s academic career exemplifies sustained scientific excellence, leadership, and international collaboration. Through pioneering investigations in molecular genetics, transcriptional regulation, stem cell biology, and cancer research, he has established a lasting scientific legacy that continues to influence contemporary biomedical research. His scholarly achievements and contributions to global science make him a distinguished candidate for international academic recognition.[1]

References

  1. Elsevier. (n.d.). Scopus Author Details: Kazunari K. Yokoyama, Author ID 7401877315. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=7401877315
  2. Yokoyama, K.K. Curriculum Vitae and Professional Academic Record.
    https://scholar.google.com/citations?user=3JIMA5EAAAAJ&hl=en
  3. Yokoyama, K.K. et al. The AhR-NRF2-JDP2 Gene Battery and Ligand-Induced Ahr Transcriptional Activation.

Amir Abaas Momtazi-Borojeni | Biotechnology | Best Researcher Award

Assist. Prof. Dr. Amir Abaas Momtazi-Borojeni | Biotechnology | Best Researcher Award

Faculty Member from Neyshabur university of medical sciences, Iran

Dr. Amir Abbas Momtazi-Borojeni is an Assistant Professor of Medical Biotechnology at Neyshabur University of Medical Sciences in Iran. Born on September 17, 1985, in Isfahan, Iran, he has established a distinguished career in medical biotechnology, focusing on nanomedicine, immunotherapy, and phytomedicine. With over 160 publications and more than 7,000 citations, his research has significantly contributed to the fields of cardiovascular and metabolic diseases. His work on PCSK9-targeted therapies and nanoliposomal drug delivery systems has been recognized internationally. Dr. Momtazi-Borojeni’s interdisciplinary approach integrates molecular biology, pharmacology, and bioinformatics, reflecting his commitment to advancing medical science through innovative research.

Professional Profile​

Education

Dr. Momtazi-Borojeni’s academic journey began with a BSc in Biology from Isfahan University (2004–2008), followed by an MSc in Microbial Biotechnology from the same institution (2008–2010). He then pursued a Ph.D. in Medical Biotechnology at Mashhad University of Medical Sciences (2013–2019), where his research focused on developing nanoliposome-based vaccines targeting PCSK9 for lipid-lowering and anti-atherosclerotic effects. His doctoral work combined immunology, nanotechnology, and cardiovascular research, laying the foundation for his future contributions to medical biotechnology.

Professional Experience

Dr. Momtazi-Borojeni has held various research and academic positions, including roles as a genomics lab expert at the Biotechnology Research Institute in Esfahan and as a part-time researcher at the Pharmaceutical Sciences Research Center of Isfahan University of Medical Sciences. He has also taught courses in cellular and molecular biology, genetic engineering, and bioinformatics at Isfahan University and Islamic Azad University, Neyshabur branch. Currently, he serves as an Assistant Professor at Neyshabur University of Medical Sciences, where he continues to advance research in medical biotechnology.

Research Interests

Dr. Momtazi-Borojeni’s research interests encompass nanomedicine, immunotherapy, and phytomedicine, with a particular focus on developing innovative treatments for cardiovascular and metabolic diseases. His work on PCSK9-targeted therapies, including vaccine development and siRNA delivery systems, aims to provide alternative strategies for managing hypercholesterolemia and atherosclerosis. Additionally, he explores the therapeutic potential of natural compounds and bioinformatics approaches to identify novel drug targets and understand disease mechanisms.

Research Skills

Dr. Momtazi-Borojeni possesses a diverse skill set that includes expertise in nanotechnology-based drug delivery, molecular biology techniques, immunological assays, and bioinformatics analysis. His proficiency in designing and characterizing nanoliposomes, conducting in vivo studies, and analyzing gene expression profiles enables him to undertake complex research projects that bridge multiple disciplines. His collaborative work with international researchers further demonstrates his ability to contribute to multidisciplinary teams and advance scientific knowledge.

Awards and Honors

While specific awards and honors are not detailed in the provided information, Dr. Momtazi-Borojeni’s extensive publication record and citation metrics reflect his significant impact on the field of medical biotechnology. His research has been published in reputable journals, and his contributions to the development of PCSK9-targeted therapies have garnered international recognition. His active participation in scientific communities and collaborations with researchers worldwide underscore his commitment to advancing medical science.

Conclusion

Dr. Amir Abbas Momtazi-Borojeni’s extensive research in medical biotechnology, particularly in the areas of nanomedicine and immunotherapy, positions him as a strong candidate for the Best Researcher Award. His innovative approaches to treating cardiovascular and metabolic diseases, combined with his interdisciplinary expertise and collaborative spirit, have significantly advanced the field. While specific awards and honors are not listed, his prolific publication record and international collaborations attest to his contributions to medical science. Continued support for his research endeavors will likely yield further breakthroughs in therapeutic strategies and enhance our understanding of complex diseases.

Publications Top Notes

  1. Therapeutic effects of curcumin in inflammatory and immune‐mediated diseases: A nature‐made jack‐of‐all‐trades?

    • Authors: E. Abdollahi, A.A. Momtazi, T.P. Johnston, A. Sahebkar

    • Year: 2018

    • Citations: 302

  2. Effects of curcuminoids plus piperine on glycemic, hepatic and inflammatory biomarkers in patients with type 2 diabetes mellitus: a randomized double-blind placebo-controlled trial

    • Authors: Y. Panahi, N. Khalili, E. Sahebi, S. Namazi, L.E. Simental-Mendía, M. Majeed, A. Sahebkar

    • Year: 2018

    • Citations: 257

  3. Curcumin as a MicroRNA regulator in cancer: a review

    • Authors: A.A. Momtazi, F. Shahabipour, S. Khatibi, T.P. Johnston, M. Pirro, A. Sahebkar

    • Year: 2016

    • Citations: 256

  4. Curcumin: A natural modulator of immune cells in systemic lupus erythematosus

    • Authors: A.A. Momtazi-Borojeni, S.M. Haftcheshmeh, S.A. Esmaeili, T.P. Johnston, A. Sahebkar

    • Year: 2018

    • Citations: 233

  5. Isolation, identification, and characterization of cancer stem cells: A review

    • Authors: M.R. Abbaszadegan, V. Bagheri, M.S. Razavi, A.A. Momtazi, A. Sahebkar

    • Year: 2017

    • Citations: 228

  6. Curcumin: a potentially powerful tool to reverse cisplatin-induced toxicity

    • Authors: R. Rezaee, A.A. Momtazi, A. Monemi, A. Sahebkar

    • Year: 2017

    • Citations: 199

  7. Cardioprotective microRNAs: Lessons from stem cell-derived exosomal microRNAs to treat cardiovascular disease

    • Authors: A.S. Moghaddam, J.T. Afshari, S.A. Esmaeili, E. Saburi, Z. Joneidi, A. Sahebkar

    • Year: 2019

    • Citations: 196

  8. A review on the pharmacology and toxicology of steviol glycosides extracted from Stevia rebaudiana

    • Authors: A. Abbas Momtazi-Borojeni, S.A. Esmaeili, E. Abdollahi, A. Sahebkar

    • Year: 2017

    • Citations: 192

  9. Role of microRNAs in the therapeutic effects of curcumin in non-cancer diseases

    • Authors: A.A. Momtazi, G. Derosa, P. Maffioli, M. Banach, A. Sahebkar

    • Year: 2016

    • Citations: 186

  10. Difluorinated curcumin: A promising curcumin analogue with improved anti-tumor activity and pharmacokinetic profile

    • Authors: A. Abbas Momtazi, A. Sahebkar

    • Year: 2016

    • Citations: 178

Xiaoliang Jiang | Molecular Biology | Best Scholar Award

Prof. Dr. Xiaoliang Jiang | Molecular Biology | Best Scholar Award

Professor of Physiology from Institute of Laboratory Animal Sciences, China

Professor Jiang Xiaoliang is a distinguished researcher and Master’s Supervisor at the Institute of Laboratory Animal Sciences, Chinese Academy of Medical Sciences. Born in March 1987, he has built an impressive career in cardiovascular research, laboratory animal sciences, and molecular mechanisms underlying hypertension and cardiac disorders. With over a decade of dedicated research, he has contributed significantly to understanding the role of epigenetic regulation, signal transduction pathways, and disease modeling. His extensive experience in both national and international institutions has led to numerous high-impact publications in prestigious journals such as Advanced Science, Hypertension, and the Journal of the American Heart Association. Additionally, he has successfully led and participated in major research projects funded by the National Natural Science Foundation of China and the Chinese Academy of Medical Sciences. Professor Jiang’s work demonstrates a seamless integration of experimental pathology, physiology, and translational medicine. His contributions have been recognized through several awards and honors, affirming his role as a leading scholar in his field. Jiang’s continuous commitment to innovation and excellence marks him as a highly suitable candidate for distinguished research awards. His profile reflects both depth and breadth of expertise, making him a role model for aspiring scientists.

Professional Profile

Education

Professor Jiang Xiaoliang has pursued a focused and prestigious educational path aligned with his research interests in pathology, physiology, and biological sciences. He obtained his Ph.D. in Pathology and Pathophysiology from the Institute of Laboratory Animal Sciences, Chinese Academy of Medical Sciences, between September 2011 and July 2014. His doctoral studies allowed him to develop an in-depth understanding of disease mechanisms at the molecular and cellular levels, particularly within the cardiovascular system. Before his Ph.D., he earned his M.S. in Physiology from the same institute between September 2009 and July 2011, further enhancing his knowledge of bodily functions and their disruptions in disease states. His academic journey began with a B.S. in Biological Science from Shandong Normal University, completed from September 2005 to July 2009. This strong foundational background equipped him with a broad knowledge of biological principles, critical thinking skills, and experimental methodologies, setting the stage for his later specialized training. Throughout his education, Professor Jiang demonstrated academic excellence and a commitment to scientific inquiry. His educational trajectory reflects a consistent dedication to advancing his expertise in biomedical sciences, perfectly positioning him for a leading role in cutting-edge medical research.

Professional Experience

Professor Jiang Xiaoliang’s professional career is deeply rooted in the Institute of Laboratory Animal Sciences at the Chinese Academy of Medical Sciences, where he has progressively advanced through academic and research roles. Currently, he serves as a Researcher since December 2024, leading key projects and supervising postgraduate research. Previously, he was an Associate Researcher from July 2018 to December 2024, where he contributed to significant research programs and established a strong reputation in cardiovascular and hypertension research. From January 2014 to July 2018, he worked as an Assistant Researcher, during which he honed his skills in experimental design, molecular biology techniques, and disease modeling. Notably, Professor Jiang also gained international experience as a Research Assistant at the University of Maryland School of Medicine, Department of Nephrology, from August 2012 to January 2014. This exposure to an international research environment broadened his perspectives and enriched his scientific approaches. Across all his roles, Professor Jiang has demonstrated outstanding leadership, technical expertise, and a passion for translational research. His career progression reflects a consistent commitment to excellence, making significant contributions to the fields of laboratory animal science and cardiovascular medicine.

Research Interests

Professor Jiang Xiaoliang’s research interests focus primarily on cardiovascular diseases, molecular and cellular mechanisms of hypertension, cardiac hypertrophy, renal physiology, and laboratory animal model development. He is particularly interested in the epigenetic regulation of cardiac reprogramming, the role of ion channels in blood pressure regulation, and the impact of neurohormonal factors on cardiovascular health. His work explores how pathways like PI3K/Akt, PKC-mediated signaling, and Na+/H+ exchangers contribute to disease pathology, and how these mechanisms can be targeted therapeutically. Additionally, he has investigated the interplay between salt sensitivity, inflammation, and oxidative stress in the development of hypertension. Another key area of his research includes the establishment and refinement of animal models for infectious and cardiovascular diseases, aiding in the development of new therapeutic interventions. His focus on translational medicine bridges basic research findings with potential clinical applications. Furthermore, Jiang has demonstrated a keen interest in the interactions between dopamine receptor pathways and cardiovascular-renal function. Through his research, he aims to uncover novel insights that can lead to innovative treatments for complex and critical diseases.

Research Skills

Professor Jiang Xiaoliang possesses an extensive array of research skills that have greatly enhanced his scientific contributions. His expertise includes molecular biology techniques such as gene editing, nucleic acid delivery, and signal transduction pathway analysis. He is proficient in developing and utilizing animal models for cardiovascular and infectious disease studies, a critical skill in translational medicine. Jiang has demonstrated advanced capabilities in histopathology, immunohistochemistry, real-time PCR, Western blotting, and other biochemical assays essential for mechanistic studies. He is highly skilled in the analysis of epigenetic modifications and their effects on gene expression, particularly concerning cardiac reprogramming and vascular biology. Additionally, his experience includes the application of pharmacological interventions and gene therapy techniques to elucidate disease pathways and therapeutic targets. Professor Jiang’s international research experience has provided him with strong data management, statistical analysis, and collaborative project management skills. His ability to design, implement, and analyze complex experiments underscores his strength in bridging basic research with clinical relevance. Through his technical proficiency and innovative approach, Jiang continues to push the boundaries of biomedical research.

Awards and Honors

Professor Jiang Xiaoliang’s outstanding contributions to science have been recognized through numerous prestigious awards and honors. In 2022, he was awarded the “Young International Award” by the Japanese Association for Laboratory Animal Science, a testament to his significant impact on the field at an early career stage. Additionally, he received the Second Prize of the Science and Technology Achievement Award from the Chinese Association for Laboratory Animals for his role in the “Creation and Application of Animal Models for Cardiovascular Diseases.” Another notable recognition was the Second Prize of the Hebei Provincial Science and Technology Progress Award in 2019, for his work on the regulation of the Renin-Angiotensin System in multiple organ injuries. Jiang was also selected for the highly competitive Youth Talent Support Project (YESS20170157) under the China Association for Life Sciences, where he secured ¥450,000 in funding for innovative research from 2017 to 2019. These honors reflect Professor Jiang’s consistent excellence, innovation, and leadership in biomedical research. His recognition by national and international bodies illustrates his important role in advancing scientific knowledge and his strong potential for future groundbreaking contributions.

Conclusion

In conclusion, Professor Jiang Xiaoliang stands out as a highly qualified and accomplished scholar in the field of biomedical sciences, particularly cardiovascular research and laboratory animal science. His educational background, combined with extensive professional experience and a strong record of research achievements, positions him as a leader and innovator in his discipline. His ability to secure competitive funding, produce high-impact publications, and contribute meaningfully to collaborative research initiatives highlights both his scientific capabilities and leadership qualities. Professor Jiang’s recognition through various prestigious awards further attests to his contributions to the advancement of science. His research exhibits a rare combination of depth, innovation, and translational relevance. Areas where he might further strengthen his profile include expanding international collaborations and leading multi-center studies to enhance global scientific impact. Overall, Professor Jiang’s impressive career trajectory, commitment to excellence, and passion for discovery make him a strong and deserving candidate for the Best Scholar Award in Research. He embodies the qualities of an outstanding researcher who continues to make significant contributions to medical science and inspire the next generation of scientists.

Publications Top Notes

  1. Title: Enpp1 Ameliorates MAFLD by Regulating Hepatocyte Lipid Metabolism Through the AMPK/PPARα Signaling Pathway

    • Authors: Liu Xiaohui, Chen Shuai, Liu Xing, Li Yuhan, Yang Zhiwei

    • Year: 2025

  2. Title: Intestinal Gastrin/CCKBR Axis Protects Against Type 2 Diabetes by Reducing Intestinal Glucose Absorption Through the PI3K/Akt/eIF4B Signaling Pathway

    • Authors: Liu Xue, Liu Xing, Liu Yunpeng, Zhang Haizeng, Yang Zhiwei

    • Year: 2025